new drug in the treatment of cognitive impairment in patients with dementia of
the Alzheimer type.
Bergamasco B, Scarzella L, La Commare P.
III Neurological Clinic,
University of Turin, Italy.
Alzheimer's disease (AD) is a central nervous system disorder characterized by
the presence of neurofibrillary tangles, neuritic plaques and dystrophic
neurones in susceptible areas of the brain. Few options for treatment of AD
symptomatology are available. We conducted a multicenter, randomized,
double-blind, placebo-controlled, parallel trial consisting of a 90 day
treatment period followed by a 30 day single blind placebo administration and
by an optional long term period of treatment up to a year with idebenone in
open fashion. Ninety two patients entered the study and nine of them dropped
out before the first control. Treatment with idebenone was found effective on
memory, attention, and orientation and in slowing down the natural progressive
worsening of the disease. The most common side effects associated with this
treatment were insomnia, gastralgia, nausea, and anxiety. However, all adverse
effects were of mild intensity and did not require specific therapies.